Author: Aridis Admin

Aridis Pharmaceuticals, Inc. today announced that it is now actively enrolling patients in a global pivotal study of Aerucin®, the Company’s broadly reactive monoclonal antibody being developed to treat acute pneumonia caused by Gram-negative bacteria Pseudomonas aeruginosa. The randomized, double-blinded, placebo-controlled trial is ongoing in...

Aridis Pharmaceuticals, Inc. today presented top-line results of its Phase 2a trial of Salvecin™ (AR-301), its human monoclonal antibody used as an adjunct therapy for severe pneumonia caused by Staphylococcus aureus, at the ASM Microbe congress held, June 1 – 5, 2017, in New Orleans....

Aridis Pharmaceuticals, Inc. today announced positive clinical results from its Phase 1/2a study of AR-301, its fully human monoclonal antibody against Staphylococcus aureus alpha-toxin being evaluated as an adjunctive therapy in combination with standard of care antibiotics for hospital-acquired pneumonia and ventilator-associated pneumonia (“HAP” and...